← All indications
Pneumonia, Ventilator-Associated
Serious INFLAMMATION of the LUNG in patients who required the use of PULMONARY VENTILATOR. It is usually caused by bacterial CROSS INFECTION in hospitals.
Drugs by status
Approved for this indication (2)
Phase 4 trials (23)
Phase 3 trials (30)
- metronidazole
- plazomicin
- aztreonam
- carbavance
- ceftolozane
- etx2514
- aciclovir
- rifampin
- iodine
- medi4893
- norfloxacin
- nystatin
- piperacillin
- relebactam
- sulfamethoxazole
- fluconazole
- ulinastatin
- taniborbactam
- ciprofloxacin
- nacubactam
- gentamicin
- cefepime
- ertapenem
- tazobactam
- neomycin
- polymyxin b sulfate
- interferon gamma-1b
- cefiderocol
- tosatoxumab
- pralurbactam
Phase 2 trials (17)
Phase 1 trials (4)
Organizations
Organization Involved with Phase 4 Indications (21)
- SmithKline Beecham
- Merck
- Pfizer
- Chiesi
- GlaxoSmithKline
- Azad University
- Hospital Pablo Tobón Uribe
- McMaster University
- Sinaloa Pediatric Hospital
- Thammasat University
- Tunis University
- University of Athens
- Prince of Songkla University
- Wright State University
- Jiao Tong University
- K.E.M. Hospital Mumbai
- Erasmus University Rotterdam
- King Edward Memorial Hospital, Mumbai
- French Society for Intensive Care
- Johnson and Johnson
- University of Franche-Comté
Organization Involved with Phase 3 Indications (33)
- Peninsula Pharmaceuticals
- The Medicines Company
- AstraZeneca
- Shionogi
- Aridis Pharmaceuticals, Inc.
- Cubist
- IntraBiotics Pharmaceuticals
- Ain Shams University
- Changi General Hospital
- Hat Yai Medical Education Center
- Singapore General Hospital
- Universidad de Guanajuato
- University of Toronto
- Creighton University
- Fudan University
- University of Naples Frederico II
- All India Institute of Medical Sciences
- University of Limoges
- University of Toulouse
- National University of Singapore
- Hospital Joan XXIII de Tarragona, Tarragona, Spain
- Technion University
- University of Reims
- University of Paris
- University of New South Wales
- Washington University in St. Louis
- European Commission
- Department of Health and Human Services
- Nanyang Technological University
- Aix-University of Marseille
- +3 more
Organization Involved with Phase 2 Indications (25)
- Valneva
- Anbics Management-Services Ag
- Arpida AG
- Arsanis, Inc.
- Kenta Biotech Ltd
- Nektar Therapeutics
- Polyphor Ltd.
- Swiss National Science Foundation
- Clinical Evaluation Research Unit at Kingston General Hospital
- Queen's University, Belfast
- Saint-Joseph University
- Sharp HealthCare
- Universidade de Passo Fundo
- Wuhan University
- Stony Brook University
- Xiamen University
- University of Barcelona
- Canadian Institutes of Health Research (CIHR)
- The Physicians' Services Incorporated Foundation
- Physician's Services Incorporated Foundation
- University of Geneva
- People's Liberation Army of China
- Humanigen
- Tuohua Biological Technology Co. Ltd
- King Abdul-Aziz University
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (9)